What Is the TRIUMPH-1 Trial?

TRIUMPH-1 is the flagship Phase 3 clinical trial for retatrutide in the treatment of obesity. Sponsored by Eli Lilly, this trial represents the single most important study in the retatrutide development program. It is designed to confirm what the Phase 2 data strongly suggested: that retatrutide produces weight loss that goes well beyond anything currently available on the market.

Retatrutide is a first-in-class triple hormone receptor agonist. Unlike semaglutide (Wegovy), which targets only the GLP-1 receptor, or tirzepatide (Zepbound), which targets GLP-1 and GIP receptors, retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. That third receptor, glucagon, is the key differentiator. It drives energy expenditure, accelerates fat metabolism in the liver, and appears to produce meaningfully greater weight loss than dual-agonist approaches.

TRIUMPH-1 is the trial that will determine whether retatrutide earns FDA approval for obesity. The stakes could not be higher. If the results confirm the Phase 2 findings, we are looking at a medication that could help patients lose nearly a quarter of their body weight, a threshold that begins to rival surgical outcomes.

Study Design and Structure

TRIUMPH-1 is a randomized, double-blind, placebo-controlled Phase 3 trial. This is the gold standard in clinical research. Participants are randomly assigned to receive either retatrutide or a matching placebo injection, and neither the patients nor the investigators know who is receiving which treatment until the study is complete.

The trial evaluates multiple dose levels of retatrutide administered as a once-weekly subcutaneous injection. Based on the Phase 2 dose-response data, the Phase 3 program focuses on the doses that showed the strongest efficacy: the 8mg and 12mg maintenance doses, with a gradual titration schedule to manage gastrointestinal side effects during the early weeks of treatment.

The treatment duration extends to approximately 48 weeks, which is standard for obesity registration trials. This timeframe allows researchers to capture the full trajectory of weight loss, including the point at which weight typically plateaus and stabilizes.

All participants follow the same background lifestyle intervention. This typically includes dietary counseling and encouragement to increase physical activity, mirroring the real-world clinical context in which the drug would be prescribed. The placebo group receives the same lifestyle counseling, ensuring that any difference in weight loss can be attributed to the medication itself.

The study is conducted across multiple clinical sites in the United States and internationally, ensuring a diverse patient population and increasing the generalizability of the results.

Enrollment and Patient Population

TRIUMPH-1 enrolled approximately 2,300 patients, making it one of the largest obesity drug trials in recent history. This enrollment number is deliberately large. Regulatory agencies like the FDA require robust safety databases for drugs that will be prescribed to millions of people, and a trial of this size provides the statistical power needed to detect both efficacy signals and uncommon adverse events.

The enrolled population consists of adults with obesity (BMI of 30 or greater) or adults who are overweight (BMI of 27 or greater) with at least one weight-related comorbidity. Common qualifying conditions include type 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea. This broad inclusion mirrors the real-world patient population that would ultimately receive the medication.

Participants span a range of ages, ethnicities, and geographic backgrounds. This diversity is critical for understanding how retatrutide performs across different populations. Obesity is a global health crisis affecting people of every background, and a drug seeking approval needs to demonstrate efficacy and safety across that spectrum.

Exclusion criteria typically include recent bariatric surgery, use of other weight loss medications within a washout period, significant cardiovascular events in the recent past, and certain endocrine disorders that could confound the results. These criteria help ensure a clean signal from the data while still maintaining a clinically relevant study population.

With 2,300 participants, TRIUMPH-1 has the scale to detect relatively rare safety signals that smaller trials might miss. It also provides the statistical power to perform meaningful subgroup analyses, examining how the drug performs in patients with diabetes versus those without, in older versus younger patients, and in different BMI categories.

Primary and Secondary Endpoints

The primary endpoints for TRIUMPH-1 follow the standard FDA framework for obesity drug approval. There are typically two co-primary endpoints:

• Percent change in body weight from baseline at the end of the treatment period (approximately 48 weeks). This is the headline number that captures the average weight loss across the treatment group compared to placebo.
• Proportion of participants achieving at least 5% body weight loss at the end of the treatment period. The FDA considers 5% weight loss clinically meaningful, and a drug must demonstrate a statistically significant advantage over placebo on this categorical measure.

Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact:

• Proportion of participants achieving 10%, 15%, and 20% or greater weight loss
• Changes in waist circumference
• Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose
• Changes in HbA1c (a measure of average blood sugar over the preceding two to three months)
• Changes in liver enzymes and markers of hepatic health
• Patient-reported outcomes related to quality of life and physical function
• Safety and tolerability, including the incidence and severity of adverse events

The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers. The glucagon receptor activation appears to drive meaningful improvements in liver health and lipid profiles that go beyond what weight loss alone would explain.

Current Status and Timeline

As of early 2026, TRIUMPH-1 is in the final stages of the treatment period, with topline results expected to read out during 2026. Eli Lilly has indicated that the broader TRIUMPH program, which includes trials in obesity (TRIUMPH-1), type 2 diabetes (TRIUMPH-2 and TRIUMPH-3), and obesity-related conditions (TRIUMPH-4), is progressing on schedule.

TRIUMPH-4, which evaluated retatrutide in patients with obesity and knee osteoarthritis, has already reported results, providing the first Phase 3 data for the molecule. Those results, showing 28.7% weight loss at the 12mg dose, have generated enormous excitement and set a high bar for what TRIUMPH-1 might confirm in a broader obesity population.

Once TRIUMPH-1 data are available, Eli Lilly is expected to compile a regulatory submission package for the FDA. The timeline from data readout to potential approval typically spans 12 to 18 months, depending on whether the FDA grants priority review. Given the magnitude of the unmet need in obesity and the strength of the data seen so far, priority review is a realistic possibility.

If all goes well, retatrutide could receive FDA approval for obesity treatment in late 2027 or 2028. This would make it the third major incretin-based obesity drug to reach the market, following semaglutide (Wegovy) and tirzepatide (Zepbound), but the first to leverage the full triple-agonist mechanism.

What Phase 2 Data Tells Us to Expect

The Phase 2 trial of retatrutide, published in The New England Journal of Medicine in 2023, provided an unusually clear preview of what TRIUMPH-1 might deliver. In that study of 338 participants, the highest dose group (12mg) achieved an average weight loss of 24.2% at 48 weeks. The weight loss curves were still trending downward at the study's end, suggesting that even greater losses might be seen with longer treatment.

Several specific findings from Phase 2 shape our expectations for TRIUMPH-1:

Dose-dependent weight loss. The Phase 2 trial tested doses ranging from 0.5mg to 12mg. Weight loss scaled consistently with dose: 8.7% at 1mg, 17.1% at 4mg, 22.8% at 8mg, and 24.2% at 12mg. For TRIUMPH-1, the focus on the 8mg and 12mg doses should produce results in the 22% to 25% range, with the possibility of exceeding 25% given that TRIUMPH-4 already showed 28.7%.

Extraordinary responder rates. At the 12mg dose, more than 90% of participants lost at least 10% of their body weight, and roughly 75% lost at least 15%. These responder rates are unprecedented for any weight loss medication. If TRIUMPH-1 replicates these numbers, it will solidify retatrutide as the most effective pharmaceutical weight loss intervention ever studied.

Metabolic improvements beyond weight. Phase 2 showed dramatic improvements in liver fat (86% reduction at 12mg), blood pressure, triglycerides, and insulin sensitivity. These benefits likely reflect the unique contribution of the glucagon receptor, which is particularly active in hepatic fat metabolism. We expect TRIUMPH-1 to confirm these metabolic benefits in a larger population.

Manageable side effect profile. Gastrointestinal adverse events (nausea, diarrhea, constipation) were the most common side effects in Phase 2, consistent with the GLP-1 class. These were generally mild to moderate and most common during the dose-escalation phase. Dropout rates due to adverse events were within acceptable ranges. TRIUMPH-1's larger sample size will provide a more precise picture of the safety profile.

It is important to note that Phase 3 trials sometimes produce slightly different results than Phase 2 due to differences in patient selection, study duration, and statistical methodology. However, the TRIUMPH-4 data already confirm that the Phase 3 results are tracking at or above Phase 2 levels, which is an encouraging sign for TRIUMPH-1.

Why a Triple Agonist Changes Everything

To understand why TRIUMPH-1 matters so much, you need to understand what makes retatrutide different from every other weight loss drug on the market or in development.

The current generation of highly effective weight loss drugs works through incretin hormone receptors. Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). Retatrutide targets three (GLP-1, GIP, and glucagon). Each additional receptor adds a new pathway for weight loss and metabolic improvement.

GLP-1 reduces appetite, slows gastric emptying, and improves insulin secretion. It is the foundation of the current weight loss revolution. But it only gets you so far. Semaglutide, working through GLP-1 alone, produces about 15% to 17% weight loss.

GIP appears to enhance the effects of GLP-1, improving insulin sensitivity and potentially contributing to fat metabolism. Adding GIP to GLP-1 (as tirzepatide does) pushes weight loss to about 20% to 22%.

Glucagon is the game-changer. Glucagon increases energy expenditure, meaning your body burns more calories at rest. It also drives hepatic fat oxidation, directly reducing liver fat. And it appears to shift the body's metabolic set point in ways that produce deeper and potentially more durable weight loss. Adding glucagon activation to the GLP-1/GIP combination is what pushes retatrutide to the 24% to 29% weight loss range.

This is not an incremental improvement. The jump from 15% to 25% weight loss transforms the clinical significance of the treatment. At 25% weight loss, many patients cross thresholds that eliminate obesity-related conditions entirely. Type 2 diabetes can go into remission. Sleep apnea can resolve. Joint pain from excess weight can dramatically improve. The metabolic profile can normalize.

TRIUMPH-1 is the trial that will confirm whether this triple-agonist approach delivers on its promise at scale.

TRIUMPH-1 in the Competitive Landscape

The obesity drug market has exploded in recent years. Semaglutide (Wegovy) and tirzepatide (Zepbound) are already generating tens of billions in annual revenue. The question is whether retatrutide can carve out a distinct position in this rapidly growing market.

Based on the data we have, retatrutide appears to offer several advantages:

Greater weight loss magnitude. If TRIUMPH-1 confirms 24% or greater weight loss, retatrutide will clearly surpass both semaglutide (approximately 15% to 17%) and tirzepatide (approximately 20% to 22%) in head-to-head comparisons of their pivotal trial data.

Superior metabolic benefits. The liver fat reduction data from Phase 2 (86% at 12mg) far exceeds what has been reported for other GLP-1 or dual-agonist drugs. This positions retatrutide as a potential treatment for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD), a condition affecting roughly 30% of the global population.

Higher responder rates. The Phase 2 data showed that more than 90% of patients at the highest dose achieved at least 10% weight loss. This means fewer non-responders and more predictable outcomes for prescribers and patients alike.

Retatrutide also faces competition from other pipeline molecules. Amgen's MariTide, Pfizer's danuglipron, and several other candidates are advancing through clinical trials. But none of these share retatrutide's triple-agonist mechanism, and none have produced Phase 2 weight loss data that approaches the 24% benchmark.

TRIUMPH-1 will be the definitive data package that either cements retatrutide's position as the next standard of care or raises questions about whether the Phase 2 magic holds up at scale.

Significance for Obesity Treatment

Obesity affects more than 40% of American adults and is the upstream driver of dozens of chronic conditions, from type 2 diabetes and cardiovascular disease to certain cancers and musculoskeletal disorders. For decades, the medical community has understood that obesity is a chronic disease requiring medical treatment, but the available therapies have been underwhelming.

Bariatric surgery remains the most effective intervention for severe obesity, producing 25% to 35% weight loss that is durable over years. But surgery carries real risks, requires hospitalization, is irreversible, and is accessible to only a small fraction of the people who could benefit from it.

Retatrutide, if TRIUMPH-1 confirms the Phase 2 and TRIUMPH-4 data, could bring surgery-level weight loss to a weekly injection. That is a transformative proposition. It means that the millions of people with obesity who are not candidates for surgery, or who prefer a non-surgical approach, could access comparable results through a pharmacological treatment.

Beyond weight loss itself, the metabolic benefits of retatrutide have implications for cardiovascular risk reduction, liver disease prevention and treatment, diabetes management, and joint health. We are moving beyond "weight loss drugs" toward comprehensive metabolic therapies that address the root causes of multiple chronic conditions simultaneously.

TRIUMPH-1 is the trial that will determine whether that vision becomes reality for retatrutide.

The FormBlends Perspective

At FormBlends, we follow the clinical trial landscape closely because it directly informs how we serve our patients. We are a physician-supervised telehealth platform specializing in GLP-1 weight loss medication and peptide wellness therapy. Our clinical team evaluates the evidence behind every treatment we offer, and trials like TRIUMPH-1 shape our understanding of where this field is heading.

Retatrutide is not yet approved or available for clinical use. But the data emerging from the TRIUMPH program is shaping the future of obesity medicine. We believe that patients deserve access to clear, accurate information about these developments so they can make informed decisions about their own care.

If you are currently exploring medical weight loss options, the treatments available today, including GLP-1 medications like semaglutide and tirzepatide, already offer meaningful, evidence-based results. Our physicians work with each patient individually to identify the right treatment approach based on their health history, goals, and preferences.

We will continue to monitor TRIUMPH-1 and the broader retatrutide development program as data becomes available. When new treatments are approved, we will evaluate them for inclusion in our clinical protocols based on the evidence, not the hype.

If you have questions about GLP-1 medications, weight loss treatment, or how emerging therapies like retatrutide might affect your options in the future, our clinical team is here to help.

References and Further Reading

• Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526.
• Eli Lilly and Company. TRIUMPH clinical trial program for retatrutide. ClinicalTrials.gov.
• Coskun T, et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist for the treatment of type 2 diabetes mellitus. The Lancet. 2022.
• Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. 2023;402(10401):529-544.